AMG 404 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

July 19, 2022

Study Completion Date

November 2, 2023

Conditions
Advanced Solid Tumors
Interventions
DRUG

AMG 404

AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.

Trial Locations (34)

2050

Chris OBrien Lifehouse, Camperdown

2650

Universitair Ziekenhuis Antwerpen, Edegem

5011

The Queen Elizabeth Hospital, Woodville South

11217

Taipei Veterans General Hospital, Taipei

27157

Wake Forest University Health Sciences, Winston-Salem

28046

Hospital Universitario La Paz, Madrid

33305

Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan District

34010

Koc Universitesi Hastanesi, Istanbul

35100

Ege Universitesi Ilac Gelistirme ve Farmakokinetik Arastirma Uygulama Merkezi (ARGEFAR), Izmir

40202

University of Louisville James Graham Brown Cancer Center, Louisville

77030

University of Texas MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute at HealthONE, Denver

90403

Sarcoma Oncology Research Center LLC, Santa Monica

119074

National University Hospital, Singapore

169610

National Cancer Centre Singapore, Singapore

40170-110

Nucleo de Oncologia da Bahia, Salvador

90610-000

Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre

15090-000

Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto

01308-050

Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo

22793-080

Instituto Coi, Rio de Janeiro

T2N 4N2

Tom Baker Cancer Centre, Calgary

277-8577

National Cancer Center Hospital East, Kashiwa-shi

791-0280

National Hospital Organization Shikoku Cancer Center, Matsuyama

641-8510

Wakayama Medical University Hospital, Wakayama

80-214

Uniwersyteckie Centrum Kliniczne, Gdansk

02-781

Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warsaw

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic University of Korea Seoul St Marys Hospital, Seoul

08035

Hospital Universitari Vall d Hebron, Barcelona

06200

Doktor Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara

W1G 6AD

Sarah Cannon Research Institute UK, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03853109 - AMG 404 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter